DUK
55
-2
PSA
53
-3
MLM
63
2
ACN
56
-3
HD
41
6
HUM
33
-3
HIG
52
-4
LB
40
-4
CMA
70
2
ETN
67
4
MNST
56
-3
VRSK
32
-3
CVS
44
4
CF
48
3
BAX
42
-5
ORLY
50
2
VZ
55
5
TXN
66
-2
CAT
76
2
MHK
53
-9
DUK
55
-2
PSA
53
-3
MLM
63
2
ACN
56
-3
HD
41
6
HUM
33
-3
HIG
52
-4
LB
40
-4
CMA
70
2
ETN
67
4
MNST
56
-3
VRSK
32
-3
CVS
44
4
CF
48
3
BAX
42
-5
ORLY
50
2
VZ
55
5
TXN
66
-2
CAT
76
2
MHK
53
-9
Financhill
Back

BridgeBio Pharma, Inc. 10K Form

Buy
60

BBIO
BridgeBio Pharma, Inc.

Last Price:
$74.79
Seasonality Move:
-0.12%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BBIO News And Ratings

See the #1 stock for the next 7 days that we like better than BBIO

BBIO Financial Statistics

Sales & Book Value

Annual Sales: $221.9M
Cash Flow: $-112.4M
Price / Cash Flow: 0
Annual Sales: $-10.04
Price / Book: 0

Profitability

EPS (TTM): -4.18690
Net Income (TTM): $-805.7M
Gross Margin: $214.3M
Return on Equity: 0%
Return on Assets: -88.65%

BridgeBio Pharma, Inc. Earnings Forecast

Key BridgeBio Pharma, Inc. Financial Ratios

  • The Gross Profit Margin over the past 8 years for BBIO is 96.60%.
  • The Selling, General & Administrative Expenses for BBIO have been equal to 130.21% of Gross Profit Margin.
  • The Research & Development expenses have been 228.24% of Revenue.
  • The Net Earning history of BBIO is -244.86% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

BridgeBio Pharma, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BBIO
CUSIP: 10806X
Website: bridgebio.com

Debt

Debt-to-Equity Ratio: -1.4
Current Ratio: 3.88
Quick Ratio: 3.52

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BBIO Technical Analysis vs Fundamental Analysis

Buy
60
BridgeBio Pharma, Inc. (BBIO) is a Buy

Is BridgeBio Pharma, Inc. a Buy or a Sell?